Fusion Antibodies plc (FAB.L), the provider of services for pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has warned that its FY24 H1 revenue is c. 23% below expectations at no less than £541k (vs £700k forecast). This reflects the weak trading environment and certain one-off delays associated with some contracts. Given that the investment case depends on a turnaround in trading – which is only just starting to materialise - we hav ....
![working](/images/WorkingLarge.gif)
13 Nov 2023
Allenby Capital: Fusion Antibodies - Update
![](/images/orange-lock.png)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Allenby Capital: Fusion Antibodies - Update
Fusion Antibodies Plc (FAB:LON) | 3.4 0 0.0% | Mkt Cap: 3.24m
- Published:
13 Nov 2023 -
Author:
Robin Davison | John Savin -
Pages:
4 -
Fusion Antibodies plc (FAB.L), the provider of services for pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has warned that its FY24 H1 revenue is c. 23% below expectations at no less than £541k (vs £700k forecast). This reflects the weak trading environment and certain one-off delays associated with some contracts. Given that the investment case depends on a turnaround in trading – which is only just starting to materialise - we hav ....